HCRN investigators presented results from the HCRN-LUN21-497 study as a poster at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, held November 8–10, 2024, in San Diego, California.
The investigator-initiated phase II trial, led by Jeffrey M. Clarke, MD, of Duke Cancer Institute. evaluated the safety and clinical activity of GT103 in combination with pembrolizumab in patients with refractory, metastatic non-small cell lung cancer. The combination was well-tolerated and showed signs of clinical activity, including durable responses in patients previously treated with checkpoint inhibitors.
Abstract Summary:
- Title: Results from a phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer
- Authors: Jeffrey M Clarke, Ryan Gentzler, Lin Gu, Alberto Chiappori, Frank Weinberg, Gregory Durm, Sarada Gurubhagavatula, Thomas Stinchcombe, James Herndon, Hirva Mamdani
- See full abstract: https://jitc.bmj.com/content/12/Suppl_3/A1717
Congratulations to Dr. Clarke and all co-authors and study teams who contributed to this study.
Learn more: https://hoosiercancer.org/all-clinical-trials/hcrn-lun21-497/
About Hoosier Cancer Research Network:
Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.
